09.07.2010 • NewsMerck & Co.restructuringsite closure

Merck & Co Closing Sites In Post-Merger Restructuring

Merck & Co announced plans to close eight research sites and eight manufacturing sites as it restructures in the wake of its merger with rival drugmaker Schering-Plough Corp. Merck's research network will include 16 major research and development facilities in the U.S., Belgium, England, France, Switzerland, Singapore and Japan. Merck will cut its manufacturing network from 91 facilities at the close of the deal in November to 77 facilities.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read